Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.48 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.48 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4392316 | 0.93 | GNAI3 (0.52) | KEAP1SMN1; SMN2ALOX15GNAI3GNAO1 | |
| SCHEMBL4395108 | 0.90 | KEAP1 (0.54) | KEAP1SMN1; SMN2ALOX15GNAI3GNAO1 | |
| SCHEMBL6277287 | 0.88 | GNAI3 (0.63) | KEAP1SMN1; SMN2ALOX15GNAI3GNAO1 | |
| SCHEMBL101501 | 0.87 | KEAP1 (0.67) | KEAP1SMN1; SMN2ALOX15SIGMAR1CYP2D6 | |
| SCHEMBL1616800 | 0.87 | — | — | |
| SCHEMBL1935309 | 0.85 | KEAP1 (0.54) | KEAP1SMN1; SMN2ALOX15GNAI3GNAO1 | |
| SCHEMBL4396498 | 0.84 | ALOX15 (0.72) | ALOX15GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL15329386 | 0.84 | KEAP1 (0.64) | KEAP1SMN1; SMN2ALOX15SIGMAR1CYP2D6 | |
| SCHEMBL6659154 | 0.84 | GNAI3 (0.50) | GNAI3GNAO1GNAI1SIGMAR1 | |
| SCHEMBL6656231 | 0.84 | GNAI3 (0.56) | GNAI3GNAO1GNAI1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328093-B2 | Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications | HYBRIGENICS SA (FR) | 2016-05-03 | — | — | US | claimed |
| US-20150072973-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | HYBRIGENICS SA (FR) | 2015-03-12 | — | — | US | claimed |
| WO-2024136309-A1 | IONIZABLE LIPID AND USE THEREOF | GREEN CROSS CORPORATION (KR) | 2024-06-27 | — | — | WO | disclosed |
| CN-114957279-B | Dihydrothieno [2,3-e ] indazole compound, pharmaceutical composition and application | 中国人民解放军军事科学院军事医学研究院 | 2023-08-01 | — | — | CN | disclosed |
| WO-2023133089-A1 | IONIZABLE LIPIDS FOR MULTIPLE ORGAN TARGETING | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-3660004-B1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-114957279-A | Dihydrothieno [2,3-e ] indazole compound, pharmaceutical composition and application | 中国人民解放军军事科学院军事医学研究院 | 2022-08-30 | — | — | CN | disclosed |
| WO-2018140809-A1 | MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018118598-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES | Arvinas, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-9884863-B2 | STAT3 inhibitor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-02-06 | — | — | US | disclosed |
| US-20070054084-A1 | Optical recording medium and compound used for the same | MITSUI CHEMICALS, INC. (JP) | 2007-03-08 | — | — | US | disclosed |
| EP-1672626-A1 | OPTICAL RECORDING MEDIUM AND COMPOUND USED IN THE OPTICAL RECORDING MEDIUM | Mitsui Chemicals, Inc. (JP) | 2006-06-21 | — | — | EP | disclosed |
| US-6479482-B2 | 4-(3-((((3-(4-((3-METHYLBUTYL)AMINO)-1-PIPERIDINYL)PROPYL) -AMINO)-CARBONYL)AMINO)PHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5 -PYRIDINEDICARBOXYLIC ACID, DIMETHYL ESTER DIHYDROCHLORIDE, FOR EXAMPLE; ANOREXIANT; NEUROPEPTIDE Y (NPY) | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-12 | — | — | US | disclosed |
| US-20020019384-A1 | Alkylamine derivatives of dihydropyridine NPY antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-14 | — | — | US | disclosed |
| WO-2001085173-A1 | ALKYLAMINE DERIVATIVES OF DIHYDROPYRIDINE NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
| EP-0629607-B1 | Compounds containing tertiary amino groups, process for their preparation and use as catalyst | BAYER AG (DE) | 2001-10-31 | — | — | EP | disclosed |
| US-5482979-A | CATALYSTS OR PROMOTERS FOR POLYURETHANE FOAMS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-01-09 | — | — | US | disclosed |
| EP-0629607-A2 | Compounds containing tertiary amino groups, process for their preparation and use as catalyst | BAYER AG (DE) | 1994-12-21 | — | — | EP | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019384-A1 | Alkylamine derivatives of dihydropyridine NPY antagonists | NPY1R, NPY2R, NPY4R | KEAP1 3493/4885SMN1; SMN2 2849/4885ALOX15 2207/4885 |
| US-20150072973-A1 | NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS | USP7, SENP7, PSMA7 | KEAP1 637/4885SMN1; SMN2 2877/4885ALOX15 4233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.